The FDA flagged at least five cases of severe or very severe RSV lower respiratory tract infections in infants immunized with ...

Norovirus vaccines face significant hurdles, with virtually no success from past efforts from HilleVax and Vaxxart. But ...

2024 has been a generally outstanding year for the stock market, with the S&P 500 ( ^GSPC 0.82%) up by nearly 30% year to ...

Moderna Inc. closed $127.61 below its 52-week high ($170.47), which the company achieved on May 24th.

Analysts issued an Underperform rating for shares while reluanching coverage of large-cap U.S. pharma and biotech names.

A briefing document from the Food and Drug Administration (FDA) says that enrollment for all clinical studies of vaccines for ...

Moderna's (NASDAQ:MRNA) mRNA-1647, its vaccine asset for cytomegalovirus (CMV), may not yield positive interim phase 3 data ...

Shares of Moderna Inc. MRNA slipped 9.07% to $41.51 Tuesday, on what proved to be an all-around grim trading session for the ...

If you want to stay updated on the latest options trades for Moderna, Benzinga Pro gives you real-time options trades alerts.

On Tuesday, Moderna Inc (MRNA) stock saw a decline, ending the day at $41.51 which represents a decrease of $-4.14 or -9.07% from the prior close of $45.65. The stock opened at $45.36 and touched a ...

MinterEllison has advised Moderna in relation to its new mRNA manufacturing facility – a facility described by the firm as ...

BofA reinstated coverage of Moderna (MRNA) with an Underperform rating and $41 price target calling it “a tough time to be a vaccines ...